Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products
Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced it received approval from the FDA to begin Phase II of its U.S. IDE clinical study evaluating the use of its Renuvion® technology in skin laxity procedures in the neck and submental region.
“We are pleased to announce that the FDA has approved our supplement and we can now move forward with Phase II of our IDE study evaluating the use of our Renuvion® technology for skin laxity procedures in the neck and submental region,” said Charlie Goodwin, President and Chief Executive Officer. “The approved supplement included changes to the treatment protocol based on feedback from study investigators during Phase I of the study, an updated statistical analysis plan and an increase in the number of investigational sites. We expect to begin enrollment of 65 study subjects in early December and plan to update the investment community upon completion of enrollment which we currently target occurring in the third quarter of 2021.”
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. The company’s Helium Plasma Technology is marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® offers surgeons and physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma® system allows surgeons to operate with a high level of precision while minimizing unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers.
Source: Company Press Release